Tag: capital

SHREWSBURY, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a decentralized infrastructure project integrating artificial intelligence and blockchain, has announced the launch of its Bonus Round following the successful completion of 15 presale stages. The project has raised a total of $21.1 million in early participation, with the Bonus Round now open at a fixed price of $0.007 per token.

$3 million upfront with up to an additional $2.9 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

New service offers wide and locally curated catalog of live and on-demand  PBS and WETA programming

ROAD TOWN, Virgin Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Global leading cryptocurrency exchange BloFin is pleased to announce the integration of Apple Pay into its Buy Crypto feature, offering users a faster, simpler, and more secure way to purchase digital assets.

Transaction brings total financing commitments across Alterra’s fully discretionary IOS funds to over $1.5 billion

Rehovot, Israel, July 16, 2025 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH) (“Steakholder Foods” or the “Company”), a leading innovator in alternative proteins and 3D printing technologies, today announced the pricing of a public offering of an aggregate of 2,380,954 of the Company’s American Depository Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company (or ADS equivalents in lieu thereof), and accompanying warrants to purchase up to 2,380,954 of the Company’s ADSs, at a combined public offering price of $1.05 per ADS (or ADS equivalent in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.05 per ADS, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about July 17, 2025, subject to the satisfaction of customary closing conditions. 

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.